🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

UMGCCC was recognized by NRG Oncology, a major research group within the NCI's National Clinical Trials Network, as a top "main member" site to enroll patients in NRG trials, many involving radiation therapy. It ranked #3 of 10 sites in the U.S. and Canada. umms.com/3ThYZ6Z

💔 We are heartbroken to announce that a member of our #RadOnc community (University of Maryland Radiation Oncology Muhammad Hamza, PGY3) was recently shot and critically injured💔 After surgery, his clinical condition is improving, but his prognosis is uncertain. Continued with link to donate below:

Congratulations to this year’s residency program graduates, Drs. Jie Ding, Rebecca Krc Rebecca Krc & Bansi Savla Bansi Savla MD! Best of luck in your careers, we know that each of you will make outstanding contributions to the field of #radonc & patient care. #residency

Congratulations to Dr. Hua-Ren (Ryan) Cherng Ryan Cherng on winning the department Medical Resident Article of the Year for "Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001”. Well done, Dr. Cherng!

⚡️Today FDA approved Vorasidenib for IDH-mutant low grade gliomas When patients ask you about this drug, make sure to inform them that ▶️ risk of tumor progression at 2 years is 49% with Vorasidenib (INDIGO trial) compared to 15% with chemoRT (RTOG 9802) ▶️tumors remain stable

In this new #RedJournal article from Mark V. Mishra Ryan Cherng et al, read about an exploratory analysis of the conditional neurocognitive function failure risk in patients receiving whole brain radiotherapy for brain metastases in NRG Oncology CC001. tinyurl.com/mishrarj

Consensus Radiation Treatment Planning Guidelines Utilizing (68)Ga-DOTATATE PET/CT for Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics- Fantastic work led by ⁦Haley K. Perlow, MD⁩ ⁦Joshua D. Palmer, MD⁩ redjournal.org/article/S0360-…

Putting the brightest inquisitive minds together to find cures for cancer Mayo Clinic Neuro Mayo Clinic Mayo Clinic Comprehensive Cancer Center Johns Hopkins Neurosurgery Johns Hopkins Engineering Johns Hopkins University U Minnesota University of Maryland, Baltimore Konstantopoulos Lab #washDC Paola Suárez Meade, MD Guerrero-Cazares lab Honggang Cui Mayo Clinic Ventures Inspiring

#ASCO25: CAN-2409, a gene therapy that induces immunogenic tumor cell death, cut recurrence/death risk by 30% (HR 0.7, p=0.0155) in int/high-risk localized prostate cancer when added to RT±ADT. 80% path CR vs 63.6% with SoC. Low added toxicity. #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO25 PROs from OUTBACK (N=919) show adding adjuvant chemo to CRT in LACC ↑ toxicity (e.g neuropathy) without OS gain. Long-term issues—sexual dysfunction, fatigue, pain—persisted through year 3. Survivorship care in #radonc must address unmet needs. 🔗 meetings.asco.org/abstracts-pres…

#ASCO25 Phase III SWOG/NRG Oncology S1914 trial shows adding atezolizumab to SBRT in early-stage NSCLC did not improve OS or PFS. More grade ≥3 AEs & local failures seen with IO+SBRT vs SBRT . First major phase III to test this combo—results are cautionary 🔗 meetings.asco.org/abstracts-pres…

#ASCO25: In COG ACNS1123, children with NGGCT treated with proton vs. photon WVRT had significantly better long-term IQ outcomes. First prospective data showing protons preserve cognition in pediatric brain RT. Photon RT linked to IQ decline over time. 🔗 meetings.asco.org/abstracts-pres…

#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO25: In Phase III KEYNOTE-630, adjuvant pembrolizumab after surgery+RT in high-risk LA cSCC did not significantly improve RFS vs placebo (HR 0.76, p=0.072). More TRAEs with pembro (64% vs 41%). Trial stopped early for futility. #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO25 Final CATNON trial results confirm: adjuvant TMZ (not concurrent) improves OS in IDH-mut anaplastic glioma (12.5 yrs vs 1.7 yrs in IDHwt). No added benefit from concurrent TMZ. RT→adjTMZ remains standard for IDHmt, 1p/19q-intact disease #btsm 🔗 meetings.asco.org/abstracts-pres…

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗 meetings.asco.org/abstracts-pres…

#ASCO25 MR-guided FUS + TMZ OS ↑ (36.4 vs 19.1 mo) & ↑ PFS in HGG vs matched controls in Phase 1/2 trial. BB barrier opened safely in 100% of cases; cfDNA tracked disease. Promising noninvasive platform for targeted delivery UMGCCC Graeme Woodworth, MD meetings.asco.org/abstracts-pres…

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? NRG Oncology ASTRO #BreastCancer nejm.org/doi/full/10.10…

Congratulations to faculty members Dr. Mark Mishra Mark V. Mishra on receiving ARRO Educator of the Year & Dr. Junliang Xu for his Dr. Karl Prado Physics Educator of the Year Award! Thank you both for your dedication to teaching.

Congrats to this year’s #radonc medical resident grads! Colleagues celebrated during graduation dinner, where certificates & diplomas were awarded & outstanding accomplishments celebrated. Left to right: Drs. Hua-Ren Ryan Cherng Ryan Cherng, Soha Bazyar Soha Bazyar, MD, PhD & James Assif.